Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

1 hour ago 1

Soumya Eswaran

Wed, August 5, 2026 astatine 7:17 AM CDT 3 min read

Baron Capital, an concern absorption company, released its Q2 2026 capitalist missive for the "Baron Health Care Fund". A transcript of the missive is disposable to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% summation for the Russell 3000 Health Care Index and the 15.44% summation for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% connected an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong banal enactment successful pharmaceuticals, biotechnology, wellness attraction equipment, and beingness sciences tools and services supported the Fund's outperformance, though constricted vulnerability to managed attraction stocks reduced comparative returns. The Fund remains affirmative connected wellness attraction owed to improving biotechnology funding, beardown acquisition activity, recovering managed attraction margins, and maturation from an aging population, chronic disease, aesculapian innovation, and higher wellness attraction spending. In addition, delight cheque the Fund's apical 5 holdings to cognize the champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Baron Health Care Fund highlighted Apogee Therapeutics, Inc. (NASDAQ:APGE). Apogee Therapeutics, Inc. (NASDAQ:APGE) a objective signifier biotechnology company, develops caller biologics for the attraction of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and different inflammatory and immunology indications. On August 04, 2026, Apogee Therapeutics, Inc. (NASDAQ:APGE) closed astatine $134.19 per share. One-month instrumentality of Apogee Therapeutics, Inc. (NASDAQ:APGE) was 1.05% and its shares gained 269.47% implicit the past 52 weeks. Apogee Therapeutics, Inc. (NASDAQ:APGE) has a marketplace capitalization of $10.11 cardinal with a 52-week trading scope betwixt $34.34 - $134.46.

Baron Health Care Fund stated the pursuing regarding Apogee Therapeutics, Inc. (NASDAQ:APGE) in its Q2 2026 capitalist letter:

"Favorable banal enactment successful biotechnology, mostly attributable to acquisition people Apogee Therapeutics, Inc. (NASDAQ:APGE), was partially offset by higher vulnerability to this underperforming sub-industry. In June, Apogee announced an statement to beryllium acquired by AbbVie Inc. for $135.11 per share, representing a 49.5% premium implicit the anterior day's closing banal price. We sold Apogee Therapeutics, Inc. pursuing announcements that it was being acquired by AbbVie Inc."

Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far successful 2025?

Apogee Therapeutics, Inc. (NASDAQ:APGE) is not on our database of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 44 hedge money portfolios held Apogee Therapeutics, Inc. (NASDAQ:APGE) at the extremity of the first quarter which was 35 in the erstwhile quarter. While we admit the imaginable of Apogee Therapeutics, Inc. (NASDAQ:APGE) as an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article